SYRE

Conviction 80HealthcareScan · Mon, Aug 10, 2026

SYRE$105.26+0.33%

ResistanceSupportVol 14Insider sell

Vol MA14 829.9K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Spyre Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.spyre.com ↗

Price105.26

Change+0.33%

Gap+0.26%

Rel volume0.95×

Avg volume995.22K

Avg $ vol99.75M

SMA 20100.61

SMA 5091.24

SMA 20054.80

Price vs 50+15.36%

Price vs 200+92.08%

MA stackbullish

50/200 cross—

Supertrendup · 87.85

RSI (14)60

MACD hist-0.04

MACD cross—

Stoch %K / %D82 / 77

ADX (14)20

+DI / −DI20 / 14

RSI divergenceBearish

MACD divergenceBearish

ATR %+5.55%

ADR %6.10%

52w high105.26

52w low14.82

From 52w high+0.00%

Above 52w low+610.26%

New 52w highYes

SqueezeOn · 7d

Bollinger width12.39%

%B0.87

Donchian pos81.74%

Donchian high108.14

Donchian low92.37

AVWAP (52w high)104.72

vs AVWAP high+0.52%

AVWAP (52w low)56.58

vs AVWAP low+86.05%

OBV trendFlat

Chaikin MF (20)0.12

Today vs 20d0.95×

Avg vol (14d)829.89K

Avg vol (20d)995.22K

Avg $ vol (20d)99.75M

Market cap9.28B

RS 3m (vs SPY)+37.82%

RS 6m (vs SPY)+204.37%

RS line new highNo

Trend template8/8

Technical rank91.9

1 week+10.88%

1 month+7.69%

3 months+40.26%

6 months+199.72%

1 year+590.68%

YTD+244.21%

P/E-59.80

P/B8.43

P/S—

P/FCF-54.84

EPS-49.12

Div yield—

ROE-14.09%

ROA-13.23%

Debt/Eq—

Current18.53

EV/EBITDA-43.52

Gross margin—

Net margin—

Rev growth—

EPS growth25.39%

Price target118.09

Target upside12.19%

Analyst ratingBuy

Institutional101.28%

Ent. value9.12B

Revenue0

Net income-36.2M

Gross profit—

Free cash flow-169.25M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out86.84M

Employees112

ListedThu, Apr 7, 2016

Free float66.88M

Float %85.2%

Short interest12.51M

Days to cover9.0d

Short volume47.9%

Squeeze score68 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.36 vs −$0.71

Last surprise+49.3% beat

Setup gradeA

Conviction80 / 100

Pattern quality—

Tech rank91.9 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance106.62

Support83.23

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in SYRE

All disclosures →

No recent disclosed trades by Congress in SYRE. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in SYRE · 2 buys · 7 sells

Insider	Side	Shares	Value	Traded	Filed
Burrows Scott L Chief Financial Officer · Common Stock · 2026-08-03	Exercise	7.5K	$109K	2026-08-03	2026-08-05
Burrows Scott L Chief Financial Officer · Common Stock · 2026-08-03	Sell	5.1K	$486K	2026-08-03	2026-08-05
Burrows Scott L Chief Financial Officer · Common Stock · 2026-08-03	Sell	2.3K	$221K	2026-08-03	2026-08-05
Burrows Scott L Chief Financial Officer · Common Stock · 2026-08-03	Sell	100	$10K	2026-08-03	2026-08-05
Burrows Scott L Chief Financial Officer · Stock Option (Right to Buy) · 2026-08-03	Exercise	7.5K	—	2026-08-03	2026-08-05
Burrows Scott L Chief Financial Officer · Common Stock · 2026-06-25	Exercise	15K	$218K	2026-06-25	2026-06-26
Burrows Scott L Chief Financial Officer · Common Stock · 2026-06-25	Sell	5K	$436K	2026-06-25	2026-06-26
Burrows Scott L Chief Financial Officer · Common Stock · 2026-06-25	Sell	10K	$871K	2026-06-25	2026-06-26
Burrows Scott L Chief Financial Officer · Stock Option (Right to Buy) · 2026-06-25	Exercise	15K	—	2026-06-25	2026-06-26

SEC filings

EDGAR filings in SYRE · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.